Company intelligence / Profile preview

ASIA SPACE Pharmaceutical

Dalian, Liaoning, Chinaasia-space.cn ↗
Ownership
Private
Development stage
Other
01

Overview

ASIA SPACE Pharmaceutical has successfully developed a class one biologic, Enboke, for psoriasis, and an approved mouse monoclonal antibody against human interleukin-8 cream for eczema. Several preclinical assets for atopic dermatitis, eczema, and seborrheic dermatitis are in the pipeline.

Therapeutic areas
Dermatology
Modalities
Monoclonal antibodyBiologic
Industry
Biotech
02

Drug pipeline

3 assets

mouse anti-human interleukin-8 monoclonal antibody

4

2 more assets in the full pipeline.

Beyond the preview

Go deeper on ASIA SPACE Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASIA SPACE Pharmaceutical.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call